BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gougis P, Wassermann J, Spano JP, Keynan N, Funck-Brentano C, Salem JE. Clinical pharmacology of anti-angiogenic drugs in oncology. Crit Rev Oncol Hematol 2017;119:75-93. [PMID: 28916378 DOI: 10.1016/j.critrevonc.2017.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Khouri C, Mahé J, Caquelin L, Locher C, Despas F. Pharmacology and pharmacovigilance of protein kinase inhibitors. Therapie 2021:S0040-5957(21)00242-0. [PMID: 34895753 DOI: 10.1016/j.therap.2021.11.004] [Reference Citation Analysis]
2 Gougis P, Palmieri LJ, Funck-Brentano C, Paci A, Flippot R, Mir O, Coriat R. Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Crit Rev Oncol Hematol 2019;141:112-24. [PMID: 31276964 DOI: 10.1016/j.critrevonc.2019.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Balcerac A, Bihan K, Lebrun-Vignes B, Thabut D, Salem JE, Weiss N. Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database. Ann Intensive Care 2022;12:55. [PMID: 35716335 DOI: 10.1186/s13613-022-01026-4] [Reference Citation Analysis]
4 Azad AK, Zhabyeyev P, Vanhaesebroeck B, Eitzen G, Oudit GY, Moore RB, Murray AG. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth. Oncogene 2020;39:6480-92. [PMID: 32879446 DOI: 10.1038/s41388-020-01444-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Schneider BK, Boyer A, Ciccolini J, Barlesi F, Wang K, Benzekry S, Mochel JP. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer. CPT Pharmacometrics Syst Pharmacol 2019;8:577-86. [PMID: 31004380 DOI: 10.1002/psp4.12415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sayadi L, Varaei S, Babazadeh Zanjani M. The Effect of Family-Centered Supportive Program on Chemotherapy-Induced Symptoms in Patients with Acute Lymphoblastic Leukemia (ALL). Int J Hematol Oncol Stem Cell Res 2021;15:35-50. [PMID: 33613899 DOI: 10.18502/ijhoscr.v15i1.5248] [Reference Citation Analysis]
7 Largeau B, Cracowski JL, Lengellé C, Sautenet B, Jonville-Béra AP. Drug-induced peripheral oedema: An aetiology-based review. Br J Clin Pharmacol 2021;87:3043-55. [PMID: 33506982 DOI: 10.1111/bcp.14752] [Reference Citation Analysis]
8 Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther 2018;189:89-103. [PMID: 29698683 DOI: 10.1016/j.pharmthera.2018.04.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]